

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated June 16, 2021 in relation to, among others, the general mandate to repurchase (the “**Repurchase Mandate**”) shares of the Company (the “**Shares**”) granted by the shareholders of the Company at the annual general meeting of the Company held on June 16, 2021 (the “**AGM**”). Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 423,275,631 Shares, being 10% of the total issued Shares as at the date of the AGM, on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors (the “**Board**”) of the Company hereby announces that from December 16, 2021 to January 5, 2022, pursuant to the Repurchase Mandate, the Company repurchased an aggregate of 45,058,000 Shares on the Stock Exchange at the highest and lowest prices of HK\$94.35 and HK\$78.45 per Share, respectively (the “**Share Repurchase**”). The aggregate purchase price paid for the Share Repurchase was approximately HK\$3,920.2 million. The Shares repurchased under the Share Repurchase represent approximately 1.06% of the total number of issued Shares of the Company immediately prior to the Share Repurchase. The Company will subsequently cancel the repurchased Shares.

The financial position of the Company is solid and healthy. The Company believes the Share Repurchase and subsequent cancellation of the repurchased Shares can enhance the value of the Shares thereby improving the return to shareholders of the Company. In addition, the Share Repurchase reflects the confidence of the Company in its business development and the strong growth prospects. The Company believes that the Share Repurchase is in the interests of the Company and its shareholders as a whole.

The Company has conducted the Share Repurchase in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on the Stock Exchange, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and other applicable laws and regulations.

The Company may make further Share repurchases on the Stock Exchange depending on market conditions.

Shareholders and potential investors of the Company should note that any further exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any further Share repurchases or whether or not the Company will make any further repurchases at all. Therefore, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, January 5, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*